Prasugrel (Effient®) is the latest addition to the thienopyridine class of medications (e.g. clopidogrel, ticlopidine). This drug is an irreversible antagonist of P2Y12 ADP receptor on platelets; thereby inhibiting platelet activation and aggregation.
Currently, when co-administered with aspirin, prasugrel has an approved indication in Australia for prevention of atherothrombotic events in patients with acute coronary syndromes (ACS), defined as moderate to high risk unstable angina, ST-segment elevation myocardial infarct (STEMI) or non-STEMI, who are to undergo percutaneous coronary intervention (PCI).
Download the complete bulletin: Prasugrel (133) Volume 35 (12): October 12, 2009
If you like this post and what else you see on the blog please subscribe by RSS feed (the orange button) or by email. Visit my subscription page.
{ 1 comment }
